Overview

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab